Dimpna Calila Albert-Brotons

Dr. Dimpna Calila Albert-Brotons

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2005 in Heart
Verified
Journal Article
Open access
PDF file
LDL Dos
L Dos
LTL Teruel
L Teruel
IFI J Ferreira
I J Ferreira
JRJ Rodriguez-Larrea
J Rodriguez-Larrea
LML Miro
L Miro
JCJ Casaldaliga
J Casaldaliga
Objectives: To evaluate late mortality and morbidity after an atrial switch procedure for correction of transposition of the great arteries (TGA) and to assess predictive factors for adverse outcome. Setting: Tertiary referral centre. Design and patients: Retrospective follow up study of 137 patients surviving hospitalisation for TGA atrial switch procedure (Mustard or Senning) in a single institution and divided into two groups (simple and complex) depending on presurgical anatomy. Several surgical and follow up factors were evaluated during 16.7 (5.6) years’ follow up. Results: Late mortality was 5.1% (95% confidence interval 1.37% to 8.84%) with sudden death as the most common cause. No significant difference was found between Mustard and Senning procedures and between the complex and simple groups in terms of mortality. Independent predictive factors for late mortality were a history of supraventricular tachyarrhythmias and advanced New York Heart Association (NYHA) functional class during follow up. A very common finding was development of sinus node dysfunction (47.6%), which had no influence on mortality. There was little need for reintervention (5.1%) and relatively few cases of right ventricular systolic dysfunction (14.6%). During follow up, most patients (96.2%) were in NYHA functional class I–II. Conclusions: Overall long term outcomes of patients with atrial repair of TGA in the present era are encouraging in terms of late mortality and quality of life. Nevertheless, better outcomes may be offered through improved diagnostic methods for right ventricular function and better management of supraventricular tachyarrhythmias.

1 December 2014 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MMM. J. del Cerro Marín
M. J. del Cerro Marín
ARA. Sabaté Rotés
A. Sabaté Rotés
AOA. Rodriguez Ogando
A. Rodriguez Ogando
ASA. Mendoza Soto
A. Mendoza Soto
MJM. Quero Jiménez
M. Quero Jiménez
AMAntonio Moreno-Galdó
Antonio Moreno-Galdó
Rationale: There is a lack of knowledge regarding the epidemiology, clinical characterization, and survival in pediatric pulmonary hypertension. Objectives: To describe the epidemiology, outcomes, and risk factors for mortality in pediatric pulmonary hypertension in Spain. Methods: We analyzed data from the Spanish Registry for Pediatric Pulmonary Hypertension. From January 2009 to June 2012, a total of 225 patients diagnosed with pulmonary hypertension in 1998 or after were collected from 21 referral and nonreferral centers. We included all Nice etiologies, estimated incidence and prevalence of pulmonary hypertension in the Spanish pediatric population, and analyzed risk factors for mortality (Nice etiologic group, clinical and hemodynamic variables). Patients were classified as follows: group I, pulmonary arterial hypertension (n = 142; 61%); group II, left heart disease (n = 31; 14%); group III, respiratory disease (n = 41; 18%); group IV, thromboembolic pulmonary hypertension (n = 2; 1%); or group V, mostly inherited metabolic diseases (n = 10; 4.5%). Of the patients studied, 31% had multifactorial pulmonary hypertension. Measurements and Main Results: Mean age at diagnosis was 4.3 ± 4.9 years (50% < 2 yr). Survival rates at 1 and 3 years were 80 and 74% for the whole cohort, and 89 and 85% for patients with pulmonary arterial hypertension. Independent risk factors for mortality included an etiologic group other than pulmonary arterial hypertension (P < 0.001), age at diagnosis younger than 2 years old (P < 0.001), advanced functional class at diagnosis (P < 0.001), and high right atrial pressure at diagnosis (P = 0.002). Conclusions: In moderate to severe pediatric pulmonary hypertension, the prognosis is better in pulmonary arterial hypertension than in other Nice categories. In pediatric pulmonary hypertension age at diagnosis younger than 2 years is a risk factor for mortality, in addition to the previously established risk factors.

1 April 2020 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
RKRichard Kirk
Richard Kirk
ADAnne I. Dipchand
Anne I. Dipchand
RDRyan R. Davies
Ryan R. Davies
OMOliver Miera
Oliver Miera
GCGretchen Chapman
Gretchen Chapman
WZWarren A. Zuckerman
Warren A. Zuckerman

1 October 2020 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
ZAZuhair N. Al-Hassnan.
Zuhair N. Al-Hassnan.
AAAbdulrahman Almesned
Abdulrahman Almesned
STSahar Tulbah
Sahar Tulbah
AAAli Alakhfash
Ali Alakhfash
FAFaten Alhadeq
Faten Alhadeq
AAAbdullah Alwadai
Abdullah Alwadai
Background: Childhood-onset cardiomyopathy is a heterogeneous group of conditions the cause of which is largely unknown. The influence of consanguinity on the genetics of cardiomyopathy has not been addressed at a large scale. Methods: To unravel the genetic cause of childhood-onset cardiomyopathy in a consanguineous population, a categorized approach was adopted. Cases with childhood-onset cardiomyopathy were consecutively recruited. Based on the likelihood of founder mutation and on the clinical diagnosis, genetic test was categorized to either (1) targeted genetic test with targeted mutation test, single-gene test, or multigene panel for Noonan syndrome, or (2) untargeted genetic test with whole-exome sequencing or whole-genome sequencing. Several bioinformatics tools were used to filter the variants. Results: Two-hundred five unrelated probands with various forms of cardiomyopathy were evaluated. The median age of presentation was 10 months. In 30.2% (n=62), targeted genetic test had a yield of 82.7% compared with 33.6% for whole-exome sequencing/whole-genome sequencing (n=143) giving an overall yield of 53.7%. Strikingly, 96.4% of the variants were homozygous, 9% of which were found in 4 dominant genes. Homozygous variants were also detected in 7 novel candidates ( ACACB, AASDH, CASZ1, FLII, RHBDF1, RPL3L, ULK1 ). Conclusions: Our work demonstrates the impact of consanguinity on the genetics of childhood-onset cardiomyopathy, the value of adopting a categorized population-sensitive genetic approach, and the opportunity of uncovering novel genes. Our data suggest that if a founder mutation is not suspected, adopting whole-exome sequencing/whole-genome sequencing as a first-line test should be considered.

1 March 2016 in Revista Espanola de Cardiologia
Verified
Journal Article
Closed access
RBRoberto Barriales-Villa
Roberto Barriales-Villa
Juan Ramón GimenoJuan Ramón Gimeno
Juan Ramón Gimeno
EZEsther Zorio-Grima
Esther Zorio-Grima
TRTomás Ripoll-Vera
Tomás Ripoll-Vera
AEArtur Evangelista-Masip
Artur Evangelista-Masip
PGPablo García-Pavía
Pablo García-Pavía

1 March 2022 in Cardiology in the Young
Verified
Journal Article
Open access
PDF file
CMColin J. McMahon
Colin J. McMahon
RHRuth Heying
Ruth Heying
WBWerner Budts
Werner Budts
ACAnna Cavigelli-Brunner
Anna Cavigelli-Brunner
MSMaria Shkolnikova
Maria Shkolnikova
OMOrnella Milanesi
Ornella Milanesi
Background: Limited data exist on training of European paediatric and adult congenital cardiologists. Methods: A structured and approved questionnaire was circulated to national delegates of Association for European Paediatric and Congenital Cardiology in 33 European countries. Results: Delegates from 30 countries (91%) responded. Paediatric cardiology was not recognised as a distinct speciality by the respective ministry of Health in seven countries (23%). Twenty countries (67%) have formally accredited paediatric cardiology training programmes, seven (23%) have substantial informal (not accredited or certified) training, and three (10%) have very limited or no programme. Twenty-two countries have a curriculum. Twelve countries have a national training director. There was one paediatric cardiology centre per 2.66 million population (range 0.87–9.64 million), one cardiac surgical centre per 4.73 million population (range 1.63–10.72 million), and one training centre per 4.29 million population (range 1.63–10.72 million population). The median number of paediatric cardiology fellows per training programme was 4 (range 1–17), and duration of training was 3 years (range 2–5 years). An exit examination in paediatric cardiology was conducted in 16 countries (53%) and certification provided by 20 countries (67%). Paediatric cardiologist number is affected by gross domestic product (R2 = 0.41). Conclusion: Training varies markedly across European countries. Although formal fellowship programmes exist in many countries, several countries have informal training or no training. Only a minority of countries provide both exit examination and certification. Harmonisation of training and standardisation of exit examination and certification could reduce variation in training thereby promoting high-quality care by European congenital cardiologists.